February 3, 2006--Boston Scientific Corporation met today with the U.S. Food and Drug Administration to discuss the company's plans for responding to the Corporate Warning Letter they received on January 26, 2006. Boston Scientific Corporation acknowledged the FDA's assessment of their corporate-wide quality system and device reporting deficiencies and confirmed their commitment to resolving all issues according to an aggressive timeline. (FDA)